Browsing by author "Turner, Nicholas"
Now showing items 1-20 of 104
-
A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO).
Turner, NC; Telli, ML; Rugo, HS; Mailliez, A; Ettl, J; et al. (AMER ASSOC CANCER RESEARCH, 2019-05-01)PURPOSE: To assess talazoparib activity in germline BRCA1/2 mutation carriers with advanced breast cancer. PATIENTS AND METHODS: ABRAZO (NCT02034916) was a two-cohort, two-stage, phase II study of talazoparib (1 mg/day) ... -
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study
Fendler, A; Shepherd, STC; Au, L; Wilkinson, KA; Wu, M; et al. (NATURE PORTFOLIO, 2021-10-27) -
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study.
Fendler, A; Shepherd, STC; Au, L; Wilkinson, KA; Wu, M; et al. (NATURE PORTFOLIO, 2021-10-27)Coronavirus disease 2019 (COVID-19) antiviral response in a pan-tumor immune monitoring (CAPTURE) ( NCT03226886 ) is a prospective cohort study of COVID-19 immunity in patients with cancer. Here we evaluated 585 patients ... -
Advances and challenges in targeting FGFR signalling in cancer.
Babina, IS; Turner, NC (NATURE PORTFOLIO, 2016-11-18)Fibroblast growth factors (FGFs) and their receptors (FGFRs) regulate numerous cellular processes. Deregulation of FGFR signalling is observed in a subset of many cancers, making activated FGFRs a highly promising potential ... -
Advances in the treatment of advanced oestrogen-receptor-positive breast cancer.
Turner, NC; Neven, P; Loibl, S; Andre, F (ELSEVIER SCIENCE INC, 2017-06-17)Oestrogen-receptor-positive breast cancer is the most common subtype of breast cancer. Endocrine therapies that target the dependence of this subtype on the oestrogen receptor have substantial activity, yet the development ... -
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.
Rugo, HS; Lerebours, F; Ciruelos, E; Drullinsky, P; Ruiz-Borrego, M; et al. (ELSEVIER SCIENCE INC, 2021-04-01)BACKGROUND: Alpelisib, a PI3Kα-selective inhibitor and degrader, plus fulvestrant showed efficacy in hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer in SOLAR-1; limited data are available ... -
Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer.
Schiavon, G; Hrebien, S; Garcia-Murillas, I; Cutts, RJ; Pearson, A; et al. (AMER ASSOC ADVANCEMENT SCIENCE, 2015-11-11)Acquired ESR1 mutations are a major mechanism of resistance to aromatase inhibitors (AIs). We developed ultra high-sensitivity multiplex digital polymerase chain reaction assays for ESR1 mutations in circulating tumor DNA ... -
Assessing CSF ctDNA to Improve Diagnostic Accuracy and Therapeutic Monitoring in Breast Cancer Leptomeningeal Metastasis.
Fitzpatrick, A; Iravani, M; Mills, A; Childs, L; Alaguthurai, T; et al. (AMER ASSOC CANCER RESEARCH, 2022-03-15)PURPOSE: Cerebrospinal fluid (CSF) cytology is the gold standard diagnostic test for breast cancer leptomeningeal metastasis (BCLM), but has impaired sensitivity, often necessitating repeated lumbar puncture to confirm or ... -
Assessing HER2 Amplification in Plasma cfDNA.
Garcia-Murillas, I; Turner, NC (HUMANA PRESS INC, 2018-05-02)Digital PCR (dPCR) is a highly accurate method to determine DNA concentration. In dPCR, DNA is portioned into many discrete single entities, and these are analyzed individually for the presence or absence of a target ... -
Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer.
Barton, S; Zabaglo, L; A'Hern, R; Turner, N; Ferguson, T; et al. (SPRINGERNATURE, 2012-05-22)BACKGROUND: The immunohistochemical (IHC) 4+C score is a cost-effective prognostic tool that uses clinicopathologic factors and four standard IHC assays: oestrogen receptor (ER), PR, HER2 and Ki67. We assessed its utility ... -
Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients.
Pascual, J; Gil-Gil, M; Proszek, P; Zielinski, C; Reay, A; et al. (AMER ASSOC CANCER RESEARCH, 2023-10-13)PURPOSE: Prognostic and predictive biomarkers to cyclin-dependent kinases 4 and 6 inhibitors are lacking. Circulating tumor DNA (ctDNA) can be used to profile these patients and dynamic changes in ctDNA could be an early ... -
BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population.
Turner, NC; Alarcón, E; Armstrong, AC; Philco, M; López Chuken, YA; et al. (OXFORD UNIV PRESS, 2019-05-01)BACKGROUND: BEECH investigated the efficacy of capivasertib (AZD5363), an oral inhibitor of AKT isoforms 1-3, in combination with the first-line weekly paclitaxel for advanced or metastatic estrogen receptor-positive ... -
Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update.
Henry, NL; Somerfield, MR; Dayao, Z; Elias, A; Kalinsky, K; et al. (LIPPINCOTT WILLIAMS & WILKINS, 2022-09-20)PURPOSE: To update the ASCO Biomarkers to Guide Systemic Therapy for Metastatic Breast Cancer (MBC) guideline. METHODS: An Expert Panel conducted a systematic review to identify randomized clinical trials and prospective ... -
Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER+/HER2- Breast Cancer.
Dowsett, M; Kilburn, L; Rimawi, MF; Osborne, CK; Pogue-Geile, K; et al. (AMER ASSOC CANCER RESEARCH, 2022-01-01)PURPOSE: To determine (i) the relationship between candidate biomarkers of the antiproliferative (Ki67) response to letrozole and palbociclib alone and combined in ER+/HER2- breast cancer; and (ii) the pharmacodynamic ... -
Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial.
Schmid, P; Abraham, J; Chan, S; Wheatley, D; Brunt, AM; et al. (AMER SOC CLINICAL ONCOLOGY, 2020-02-10)PURPOSE: The phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway is frequently activated in triple-negative breast cancer (TNBC). The AKT inhibitor capivasertib has shown preclinical activity in TNBC models, and ... -
CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2- Metastatic Breast Cancer.
Guerrero-Zotano, Á; Belli, S; Zielinski, C; Gil-Gil, M; Fernandez-Serra, A; et al. (AMER ASSOC CANCER RESEARCH, 2023-04-14)PURPOSE: In hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC), it is imperative to identify patients who respond poorly to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) and to discover therapeutic ... -
CDK4/6 Inhibitors: Promising Opportunities beyond Breast Cancer.
Lim, JSJ; Turner, NC; Yap, TA (2016-07)Patnaik and colleagues report on the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of abemaciclib for the treatment of advanced solid cancers, demonstrating antitumor activity in advanced breast ... -
Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review.
Merker, JD; Oxnard, GR; Compton, C; Diehn, M; Hurley, P; et al. (COLL AMER PATHOLOGISTS, 2018-03-05)PURPOSE.—: Clinical use of analytical tests to assess genomic variants in circulating tumor DNA (ctDNA) is increasing. This joint review from the American Society of Clinical Oncology and the College of American Pathologists ... -
Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review.
Merker, JD; Oxnard, GR; Compton, C; Diehn, M; Hurley, P; et al. (LIPPINCOTT WILLIAMS & WILKINS, 2018-06-01)Purpose Clinical use of analytical tests to assess genomic variants in circulating tumor DNA (ctDNA) is increasing. This joint review from ASCO and the College of American Pathologists summarizes current information about ... -
Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer.
O'Leary, B; Cutts, RJ; Huang, X; Hrebien, S; Liu, Y; et al. (OXFORD UNIV PRESS INC, 2021-03-01)BACKGROUND: There are no established molecular biomarkers for patients with breast cancer receiving combination endocrine and CDK4/6 inhibitor (CDK4/6i). We aimed to determine whether genomic markers in circulating tumor ...